Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy (Q43115659)

14 November 2017

title

Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy (English)

1 reference

14 November 2017

1 reference

cervix uterine cancer

1 reference

10

Fumitaka Kikkawa

1 reference

14 November 2017

Tomoko Inaba

1

1 reference

14 November 2017

Kazuhiko Ino

2

1 reference

14 November 2017

Hiroaki Kajiyama

3

1 reference

14 November 2017

Kiyosumi Shibata

4

1 reference

14 November 2017

Eiko Yamamoto

5

1 reference

14 November 2017

Shinji Kondo

6

1 reference

14 November 2017

Tomokazu Umezu

7

1 reference

14 November 2017

Akihiro Nawa

8

1 reference

14 November 2017

Osamu Takikawa

9

1 reference

14 November 2017

language of work or name

English

0 references

publication date

28 March 2010

1 reference

14 November 2017

1 reference

14 November 2017

volume

117

1 reference

14 November 2017

issue

3

1 reference

14 November 2017

page(s)

423-428

1 reference

Global cancer statistics, 2002

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Management of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Treatment options in bulky stage IB cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Histopathologic parameters of prognosis in cervical cancer--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Papillomaviruses and cancer: from basic studies to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Evolving immunosuppressive microenvironment during human cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Association of cervical cancer with the presence of CD4 regulatory T cells specific for human papillomavirus antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

High Number of Intraepithelial CD8 Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Low density of CD3 , CD4 and CD8 cells is associated with increased risk of relapse in squamous cell cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8 /regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Feasibility and effectiveness of postoperative adjuvant concurrent chemoradiation therapy in Japanese patients with high-risk early-stage cancer of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2010.02.028

10.1016/J.YGYNO.2010.02.028

7 January 2021

Identifiers

DOI

1 reference

14 November 2017

1 reference